FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Titel:
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Auteur:
Stintzing, Sebastian Modest, Dominik P Rossius, Lisa Lerch, Markus M von Weikersthal, Ludwig Fischer Decker, Thomas Kiani, Alexander Vehling-Kaiser, Ursula Al-Batran, Salah-Eddin Heintges, Tobias Lerchenmüller, Christian Kahl, Christoph Seipelt, Gernot Kullmann, Frank Stauch, Martina Scheithauer, Werner Held, Swantje Giessen-Jung, Clemens Moehler, Markus Jagenburg, Andreas Kirchner, Thomas Jung, Andreas Heinemann, Volker